Skye Bioscience, a clinical-stage biopharmaceutical developing obesity and metabolic treatments, began its CBeyond Phase 2a trial in August 2024—a 26-week, randomized, double-blind, placebo-controlled study of nimacimab for obesity/overweight. The class action alleges defendants made false or misleading statements and omitted that nimacimab was less effective and its prospects were overstated. On October 6, 2025, Skye reported topline CBeyond results: the nimacimab monotherapy arm failed the primary weight-loss endpoint and preliminary pharmacokinetics showed lower-than-expected exposure, possibly requiring higher dosing; the stock fell 60%.